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ABSTRACT: It is not known whether sputum elastase, metalloproteinase (MMP)-9
and tissue-inhibitor metalloproteinase (TIMP)-1 are related to structural changes of the
airways, as assessed by high-resolution computed tomography (HRCT) scan.
The relationships between these markers and the magnitude of structural changes of
the airways in asthma and chronic obstructive pulmonary disease (COPD) were
assessed. Induced sputum and HRCT scan were performed in 30 asthmatics (14 mild
and 16 severe) and in 12 patients with COPD.
A greater extent of HRCT scan abnormalities was found in COPD than in severe
and mild asthmatics. HRCT scan abnormalities correlated with the degree of airway
obstruction in COPD and in severe asthma. HRCT scan abnormalities also correlated
with the levels of sputum elastase both in COPD and in severe asthma. HRCT scan
abnormalities were associated with sputum MMP-9/TIMP-1 ratio in mild asthma,
severe asthma and COPD.
In conclusion, this study demonstrates that sputum elastase and the metalloprotei-
nase-9/tissue-inhibitor metalloproteinase-1 ratio are associated with the magnitude of
high-resolution computed tomography scan abnormalities of the airways in asthma and
chronic obstructive pulmonary disease, and suggests that the levels of these markers
reflect the extent of structural changes of the airways.
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Asthma and chronic obstructive pulmonary disease
(COPD) share a condition of chronic inflammation of the
airways, which is followed, to various extents and with
different features, by a healing process that may lead to
airway remodelling. Although the mechanisms of remodelling
appear to be heterogeneous, an abnormal extracellular matrix
(ECM) degradation and deposition may play an important
role in the development of structural alterations of the
airways, contributing to airway stiffness and to irreversible
airflow obstruction [1]. Such remodelling within the airway
wall is to be attributed mainly to qualitative and quantitative
changes of ECM proteins, resulting from an imbalance
between proteases and their inhibitors.
Inflammation in asthma and COPD is associated with
increased production of active elastase, which can promote
fibroblast migration through the ECM, as well as the
degradation of elastic fibres [2, 3]. ECM homeostasis is also
influenced by the balance between metalloproteinases (MMP)
and their specific tissue-inhibitor metalloproteinases (TIMP),
in such a way that increases of TIMP over MMP (or vice
versa) can either lead to collagen deposition or degradation [4,
5]. In asthma and COPD, several studies have shown that
there is an increase of TIMP-1 over MMP-9 levels both in
bronchoalveolar lavage and sputum, which may be respon-
sible for a trend towards collagen deposition in the airway
wall, and for the development of an exaggerated airway
narrowing [4, 6–10]. This evidence has led to the hypothesis
that, in asthma and COPD, the imbalance between elastase
over anti-elastase, and between MMP-9 over TIMP-1, may
contribute to structural changes of the airways and to a
functional impairment; although attractive, this hypothesis
has never been tested, mainly due to the difficulties in study-
ing airway remodelling in a noninvasive fashion.
However, with the advances in the field of lung imaging,
our ability to noninvasively quantify structural changes of
the airways has been significantly improved both in asthma
and COPD [11–15], making it possible to establish a close
relationship between structural and functional abnormalities.
Indeed, in asthma, the use of high-resolution computed
tomography (HRCT) has allowed the demonstration of
several airway wall abnormalities, whose extent significantly
correlated with the clinical severity of the disease [12, 13, 16],
the impairment of lung function and the magnitude of
bronchial hyperresponsiveness [11, 17], three parameters that
are likely to be due to airway remodelling.
In order to assess, in an integrated manner, biochemical,
structural and functional parameters in the same group of
asthmatic and COPD subjects, this study was undertaken to
test the hypothesis that, in asthmatic and COPD patients, the
increased levels of active elastase, MMP-9 and TIMP-1 may
account for HRCT scan abnormalities and functional changes
that characterise these diseases.For editorial comments see page 893.
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Materials and methods
Subjects
A total of 30 asthmatic subjects were selected according to
the criteria of the American Thoracic Society [18]. Asthma
severity was assessed according to Global Initiative for
Asthma (GINA) criteria [19]. None of the subjects participat-
ing in the study was a current smoker. Subjects who had an
upper or lower respiratory tract infection during the month
preceding the test, or who experienced a severe exacerbation
of asthma resulting in hospitalisation, were excluded from the
study. For the purpose of the study, subjects were divided into
two groups. The first group consisted of 14 corticosteroid-
naı¨ve subjects (eight males, 29–69 yrs) with mild persistent
asthma, who attended the current authors9 outpatient clinic
(Dept of Respiratory Diseases, CHU Montpellier, Montpel-
lier, France) for the first time. This group was defined as
mild asthmatics. The second group consisted of 16 severe
asthmatic patients (nine males, 26–66 yrs), selected as
previously described [20]. They had persistent asthma that
required a q.d. dose of inhaled corticosteroid (2,000 mg
fluticasone propionate) or oral prednisone, long-acting b2-
agonists (100 mg salmeterol) and short-acting b2-agonists as
required. These patients were all considered as corticosteroid
dependent since, in the past 2 yrs, the attempt to wean them
from the systemic treatment had always failed (follow-up at
f3 yrs). They were studied whilst in stable clinical condi-
tions, according to the asthma-control questionnaire [21].
In total, 12 COPD patients (11 males, 48–77 yrs) took part
in the study. COPD was defined as a disorder characterised by
abnormal expiratory flow test [22] and, although no definitive
cut-off limit was available at the time of the study, only
patients with forced expiratory volume in one second (FEV1)
capacities ofv70% of the predicted values were studied. The
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) criteria were not applied since they were not
available when the study was carried out. COPD patients
with a history of perennial allergic rhinitis and/or a positive
diagnosis of immediate-type hypersensitivity [23], wheezing,
an improvement of FEV1 capacity ofw12% from baseline or
an absolute value of 200 mL following inhalation of 200 mg of
salbutamol were excluded. Smoking habit was carefully
checked, and a minimum of 20 pack-yrs smoked was required
for inclusion in the chronic bronchitis group. None of them
had any upper or lower respiratory tract infection during the
month preceding the test, and none of them was permitted to
smoke the day of study. They were in a stable condition, their
lung function being their best ever measured in the current
authors9 clinic. All investigations were performed on the same
day. The study was performed after informed consent was
obtained from the participants, and approval of the ethics
committee of the hospital was obtained.
Pulmonary function testing
Pulmonary function test was performed using a Pneumoscreen
(E. Jaeger Laboratories, Wu¨rzburg, Germany), and normal
values were analysed according to KNUDSON et al. [24].
Carbon monoxide diffusing capacity of the lung (DL,CO) was
measured using the single breath technique. Quality control
and procedures of lung function testing were performed
according to the European Respiratory Society guidelines
[25, 26]. Predicted normal values were determined using the
equations of the European Community for Steel and Coal for
all resting pulmonary function parameters [25, 26].
Chest computed tomography scan
Computed tomography (CT) scans of the chest were
performed with a spiral CT scanner (LightSpeed 16; GE
Healthcare, Paris, France) in high-resolution mode according
to the method of MAYO et al. [27], as previously used by the
current authors [12]. Briefly, only a conventional HRCT scan
during full inspiration was performed [28]. CT scans of the
chest were performed using the following parameters: 125 kV,
310 mAs, matrix size of 5126512, and a slice thickness of
1–1.25 mm. A window level of -600 Hounsfield units (HU)
was chosen, with a width of 1,600 HU, as generally recom-
mended for the analysis of the bronchi and lung parenchyma
[27, 29]. Several HRCT scan abnormalities were taken into
account, as follows: 1) bronchial abnormalities (bronchiecta-
sis) [30, 31] and thickness of peripheral bronchi [32]; 2)
emphysema (centrolobular and bullous) [33]; and 3) peri-
pheral linear hyperdensities [34]. Due to the difficulty of
staging or prioritising the impact of radiographical abnor-
malities (bronchiectasis, emphysema and others) on the
clinical outcomes of the disease [35, 36], each of the above
permanent HRCT scan abnormalities was considered as
contributing equally to the remodelling process [12, 37]. Thus,
a total score of HRCT scan abnormalities was calculated
simply by summation, as previously published [37].
CT measurements were obtained in a blind fashion by two
observers (L. Capieu and F. Paganin). The measurements
were performed once and interobserver reproducibility was
good (k=0.7).
Sputum induction
Induced sputum was carried out according to the method
of PIN et al. [38]. Sputum samples were immediately treated
with 10% dithiotreitol (Sigma Chemical, St Louis, MO, USA)
and centrifuged. The supernatants were immediately frozen
for subsequent analysis. A cytocentrifugation (Shandon,
Runcorn, UK) was done on the cell pellet, and cells were
enumerated using Diff-Quick (Imeb Inc., Chicago, IL, USA).
Total elastase was measured in sputum samples by a
homogeneous enzyme immunoassay specific for human
polymorphonuclear elastase (IMAC-Elastase; Kit Merck,
Darmstadt, Germany) using the package insert [39], as
previously described [5]. Levelsw20 mg?L-1 can be measured.
The activity of active neutrophil elastase was determined
according to the technique of FUJITA et al. [3], as previously
described [5].
Determinations of the absolute value of MMP-9 and
TIMP-1 in induced sputum were performed by ELISA
(MMP9-BIOTRAK ELISA and TIMP1-BIOTRAK ELISA;
Amersham International plc, Little Chalfont, UK), as
previously described [5]. These assays measure the total
amount of each respective protein (MMP-9 and TIMP-1),
whether free or complexed to one another or to matrix. The
limits of detection are 4–128 ng?mL-1 for MMP-9 and
3.13–50 ng?mL-1 for TIMP-1.
Statistical analysis
Results are given as medians (interquartile range). The
nonparametric Kruskall-Wallis test was used to compare the
outcomes of the study within the three groups. The Mann-
Whitney U-test was used for pairwise comparisons between
the study groups. To evaluate whether an association exists
between the biological outcomes and structural alterations
described with the HRCT scan, the nonparametric correlation
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analysis (Spearman rank test) was used. For multiple
comparisons, Bonferroni9s correction was applied. p-Values
of f0.05 were considered statistically significant.
Results
Demographic characteristics of the patients are reported in
table 1. Patients with COPD were significantly older than
both groups of asthmatics. Airflow obstruction was signifi-
cantly greater in COPD and severe asthmatics than in mild
asthmatics (pv0.001). As expected, DL,CO was significantly
decreased in COPD when compared with mild (pv0.0003)
and severe asthmatics (pv0.007). Arterial oxygen tension
(Pa,O2) was significantly lower in COPD than in severe and
mild asthma (pv0.016 and pv0.001, respectively) and in
severe asthmatics by comparison with mild asthmatics
(pv0.016).
High-resolution computed tomography scan
Eight out of 14 mild asthmatics showed HRCT scan
abnormalities with a maximal score of 5 (fig. 1). Most of the
abnormalities were related to the bronchial tree, and no
emphysema of the lung was observed.
Three severe asthmatics had a normal HRCT scan. In the
other patients, abnormalities were mainly related to bronchi,
whereas emphysema was recorded in three subjects. The
number of lesions was significantly higher than in milder
asthmatics (mean score difference: 7; pv0.003).
All COPD patients had HRCT scan abnormalities that
were mainly related to the parenchyma (emphysema), but
bronchiectasis was also observed. The total number of lesions
was significantly greater in COPD individuals as compared
with mild (mean score difference: 19; pv0.0001) and severe
asthmatics (mean score difference: 12; pv0.003).
Interestingly, HRCT findings correlated with the degree of
airway obstruction, as assessed by FEV1, in severe asthmatics
(r=-0.78, p=0.003) and the COPD subjects (r=-0.70, p=0.02),
but not in the mild asthmatic group (r=-0.03, p=0.92; fig. 2).
Also, both in the COPD group and the severe asthmatic
group, HRCT scan score significantly correlated with DL,CO
values (r=-0.53, p=0.04, and r=-0.74, p=0.01, respectively).
Cellular content in induced sputum
The cellular content is reported in table 2. The percentage
of macrophages was higher in mild asthmatics than in COPD
or severe asthmatics (pv0.001 and pv0.0004, respectively).
The percentage of neutrophils was greater in mild asthmatics
than in severe asthmatics (pv0.003). The percentage of
eosinophils was increased in severe asthma by comparison
with mild asthma (pv0.009). There was no significant
correlation between cell numbers or percentages and FEV1
levels or HRCT scan scores.
Mediator levels in induced sputum
Table 3 shows the mediator levels in induced sputum. The
levels of total elastase were higher in COPD subjects than in
severe (pv0.001) and mild (pv0.001) asthmatics. Sputum of
COPD subjects was also characterised by higher levels of
active elastase than those measured in the other two study
groups (p=0.01 and p=0.003 for severe and mild asthmatics,
respectively).
The levels of MMP-9 were not significantly different among
the three groups. Conversely, TIMP-1 was increased in
COPD and significantly higher than that of mild asthmatics
(pv0.0007). MMP-9/TIMP-1 ratio was reduced in COPD as
compared with severe and mild asthma, but the difference did
not reach statistical significance.
Nonparametric correlations within each study group showed
that active elastase levels were significantly associated with
HRCT scan score in severe asthma and in COPD (r=-0.9,
pv0.008 and r=-0.9, pv0.005, respectively; fig. 3), but not in the
mild asthmatic group (r=-0.3, p=0.19). In addition, in COPD
and severe asthmatic subjects, the levels of active elastase were
found to be inversely and significantly correlated with airway
obstruction, as assessed by FEV1 values (r=-0.6, pv0.03 and
r=-0.7, pv0.003, respectively). A significant correlation was also
found between HRCT scan score and MMP-9/TIMP-1 ratio
(mild asthma: r=-0.8, pv0.003; severe asthma: r=-0.7, pv0.004;
COPD: r=-0.6, pv0.04), although this correlation seems to be
affected by one single observation (fig. 4).
Discussion
The main result of this study is that a relationship exists
between increased levels of active elastase and overproduction
Table 1. – Demographic characteristics of the patients
MA SA COPD Statistical analysis
MA/SA MA/COPD SA/COPD
Subjects n 14 16 12
Females n 6 7 1
Age yrs 52.5 (45–58) 53.5 (35–65) 71 (56.5–72.5) NS v0.01 v0.01
Smoking pack-yrs 0 0 55 (42.5–80)
FEV1 L 3.08 (2.16–3.52) 1.44 (1.30–2.04) 1.41 (1.16–1.52) v0.001 v0.001 NS
FEV1 % pred 93 (86–100) 54.5 (44.5–62) 50.5 (45–55) v0.001 v0.001 NS
Pa,O2 mmHg 90.5 (86–95) 78.5 (73.5–90.5) 71.5 (71–78.5) v0.016 v0.001 v0.016
DL,CO % pred 103.5 (86–118) 94 (79–100) 61 (52.5–73) NS v0.0003 v0.007
CT scan score 2 (0–4) 6.5 (2.5–16) 19 (15–25.5) v0.01 v0.001 v0.01
Data are presented as median (interquartile range), unless otherwise stated. Statistical analysis was performed by the Mann-Whitney U-test and
Bonferroni9s correction. Data were considered statistically significant when pv0.016. MA: mild asthma (untreated asthma); SA: severe asthma
(corticosteroid-dependent asthma); COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in one second; Pa,O2: arterial
oxygen tension; DL,CO: carbon monoxide diffusing capacity of the lung; CT: computed tomography; NS: nonsignificant. 1 kPa=0.133 mmHg.
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of TIMP-1 over MMP-9 with HRCT abnormalities in severe
asthmatics and in COPD subjects. This observation further
supports the concept that the levels of these biological
markers of remodelling might reflect the extent of structural
changes occurring within the airways. The present study also
provides evidence in support of the usefulness of a HRCT
scan technique to assess structural alterations of the airways.
HRCT scan has been proposed as an additional tool to
assess pulmonary changes in long-standing diseases, such as
asthma and COPD [40–42]. Moreover, by differentiating
airway remodelling from parenchymal alterations, HRCT
imaging could contribute towards distinguishing between
asthma and COPD. Anatomical pulmonary changes, including
bronchial wall thickening, emphysema, and bronchiectasis,
have been demonstrated by HRCT scan in some studies
[11–13, 37]. Therefore, this technique could provide relevant
information in airway remodelling associated with a chronic
inflammation of the airways. HRCT scan has been previously
used to quantify abnormalities of the airways due to airway
remodelling and it has been found that the HRCT scan score
correlated with the severity of asthma and airflow obstruction
[12, 43]; conversely, conflicting results have been obtained on
the relationship between HRCT-documented thickness of
airway wall and hyperresponsiveness [17, 44], and, from these
results, it can be derived that the issue of airway responsive-
ness is perhaps a more complex phenomenon than airway
obstruction. The most plausible explanation for different
results among studies may depend on the method that was
employed to assess and quantify the structural alterations of
the lung. In the current study, the HRCT outcome is
represented by a final score that was obtained by counting
the number of the observed lesions. Although a significant
number of quantitative methods are now available, the
current authors have arbitrarily chosen this method because
it avoids the risk of underestimating the degree of pulmonary
involvement. Indeed, this approach has the advantage of
combining information from both airways and parenchyma.
In a study performed in COPD subjects by NAKANO et al.
[45], the evaluation of both airway wall thickness and the area
of low attenuation of the lung (to assess the severity of
emphysema) was shown to improve the estimation of
pulmonary function abnormalities. The recent advantages in
technology, with the use of new multi-slice CT scanners,
together with the use of more objective and direct measure-
ment of airway dimension and parenchymal abnormalities,
such as the assessment of lung densities by density mask or
histograms to evaluate the degree of emphysema, which are
employed by all investigators, should increase the accuracy of
the evaluation and minimise discrepancy between studies.
In the current study, it was demonstrated that HRCT scan
abnormalities are more relevant in severe than mild asthma,
suggesting that severe asthma is characterised by a greater
extent of structural abnormalities of the airway wall. In
addition, in severe asthmatics, it was shown that most of the
HRCT scan abnormalities are due to bronchial alterations,
which may play a role in the development of a severe
expiratory flow limitation. Bronchial abnormalities were also
detected by the CT scan in the COPD group. The observation
of bronchiectasis in COPD patients is not controversial.
Associations between emphysema and bronchiectasis are
frequent and related to processes of traction and cicatrisation,
reflecting a process of peri-bronchial fibrosis [46] and
abnormal synthesis and degradation of ECM proteins, such
as collagen and elastin. In the context of COPD, the current
authors were also able to assess the parenchymal involvement,
mostly emphysema. This is of great importance from a func-
tional standpoint, in that it may account for the significant
correlation between the HRCT scan alterations and the
degree of impairment in DL,CO. Taken together, quantitative
assessment of airway wall dimensions and parenchymal
alterations with HRCT could provide a valuable tool for
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Fig. 1. – Quantification of high-resolution computed tomography
(HRCT) scan score in mild asthma, severe asthma and chronic
obstructive pulmonary disease (COPD). Statistical analysis was
performed using the Mann-Whitney U-test. #: pv0.03; }: pv0.003;
z: pv0.0001.
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Fig. 2. – Correlations between forced expiratory volume in one second
(FEV1) % predicted and high-resolution computed tomography
(HRCT) scan score in a) severe asthma and b) chronic obstructive
pulmonary disease. Statistical analysis was performed using the
Spearman rank test.
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the study and the differentiation of chronic airway diseases, as
previously suggested by other investigators [42].
The main finding of the current study is the relationship
between structural alterations documented with HRCT and
biological markers of remodelling in severe asthmatics and in
COPD; in other words, the more elastase levels increase and
TIMP-1 overcomes MMP-9, the greater the magnitude of
structural alterations. This observation may have some
implications in the understanding of the pathophysiological
processes of asthma and COPD, suggesting that a common
feature of remodelling can be detected with structural
consequences in the lungs, at least in these populations. To
date, a body of evidence has accumulated information on the
potential role of an increased proteolytic burden in the
pathogenesis of structural and functional abnormalities
associated with chronic inflammatory diseases of the airways
[47, 48]. Proteolytic enzymes have the potential to destroy
lung structures and are responsible for the architectural
damage that is seen in COPD [48]. An increased elastolytic
activity seems also to occur in asthma, as shown by the
presence of elastic fibre disruption in the bronchi of mild-to-
moderate asthmatics [49]. The increased elastolytic activity in
the airways of asthmatics could induce, to various extents,
loss of the elastic recoil, increased collapsibility of the central
airways, lack of distensibility of airways, and hyperinflation,
thus variably contributing to the pathogenesis of airway
remodelling and the development of exaggerated airway
narrowing. It is also important to consider that the release
of mediators, such as elastase, in asthma may reflect cellular
activation. The current authors believe that this does not
necessarily imply the presence of radiological findings
suggestive of emphysema. Transmission electron microscopy
studies have shown that an elastolytic process is also observed
in fatal asthma, in which elastic fibre fragmentation is found
in central airways [50]. Moreover, pseudophysiological
emphysema has been found in chronic persistent asthma
[51], which may depend upon an increased elastolysis.
Collagen homeostasis is also regulated by the proteolytic
activity of MMPs, which is counterbalanced by their TIMPs
[4, 52]. It has been previously demonstrated that the MMP-9/
TIMP-1 ratio is reduced in asthmatic and COPD subjects as
compared with normal subjects, and that it is significantly
correlated with airway obstruction [2, 5]. Therefore, it was
reasoned that an abnormal increase of TIMP-1 over MMP-9
levels may be a marker of airway remodelling [5, 8], reflecting
a trend towards tissue fibrosis in the airways of these subjects.
The present study confirms this hypothesis by demonstrating
that the imbalance between MMP-9 and TIMP-1, together
with levels of active elastase, is higher in those patients in
whom the HRCT scan score is increased. This hypothesis is
also supported by the inverse correlation between MMP-9/
TIMP-1 ratio and HRCT scan score, suggesting that TIMP-1
overproduction is involved in the development of airway
remodelling in severe asthmatics and COPD subjects.
Antitrypsin was also measured to assess whether a relation-
ship exists between this factor and HRCT scan features of
airway remodelling, and, in particular, those related with the
destruction of the lung parenchyma. However, this analysis
did not yield any significant relationship. The lack of such a
relationship suggests that antitrypsin is a less sensitive marker
to detect structural alterations of the lung.
The results of the current study have also shown that
structural alterations of the airways and the parenchyma that
are assessed with the HRCT are associated with lung function
changes, as demonstrated by the significant correlation
between FEV1 values and levels of active elastase; it is
Table 2. – Cell analysis of sputum samples
MA SA COPD Statistical analysis
MA/SA MA/COPD SA/COPD
Squamous cells % 4 (2–9) 8 (3–20) 9 (1–40) NS NS NS
Total cell counts6103?mL-1 362 (246–720) 464 (203–1010) 790 (575–1490) NS NS NS
Differential cell counts %
Macrophages 16.5 (14–34) 2 (13.3–31.3) 10 (4.5–19) pv0.0004 pv0.001 NS
Neutrophils 68 (41–80) 50.5 (19.5–60.5) 58.5 (40.5–84) NS pv0.003 NS
Lymphocytes 1 (0–2) 1 (0–5.5) 2 (1–3.5) NS NS NS
Eosinophils 1 (1–3) 2.5 (1–13) 1.5 (0–4) NS pv0.009 NS
Epithelial cells 1 (0–2) 0 (0–27) 0 (0–1) NS NS NS
Data are presented as median (interquartile range), unless otherwise stated. Statistical analysis was performed using the Mann-Whitney U-test and
Bonferroni9s correction. MA: mild asthma (untreated asthma); SA: severe asthma (corticosteroid-dependent asthma); COPD: chronic obstructive
pulmonary disease; NS: nonsignificant.
Table 3. – Proteases/anti-proteases content in induced sputum
MA SA COPD Statistical analysis
MA/SA MA/COPD SA/COPD
Total elastase mg?mL-1 2 (1–10.7) 8 (4.8–11) 21 (13.2–26.5) NS p=0.001 p=0.001
Active elastase mg?mL-1 0.75 (0.2–8.2) 3.8 (0.16–9.7) 9.7 (4.5–14) NS p=0.003 p=0.01
a1-antitrypsin mg?mL-1 6 (4–12) 4 (2.8–14.2) 13.9 (12.5–14.7) NS NS pv0.004
MMP-9 mg?mL-1 48 (22–122) 82 (19–126.5) 85 (56.5–124) NS NS NS
TIMP-1 mg?mL-1 227 (143–341) 210 (150–1935) 900 (484–1280) NS p=0.0007 NS
MMP-9/TIMP-1 0.2 (0.09–0.8) 0.43 (0.04–0.67) 0.1 (0.7–0.14) NS NS NS
Data are expressed as median (interquartile range), unless otherwise stated. Statistical analysis was performed using the Mann-Whitney U-test and
Bonferroni9s correction. Data were considered statistically significant when pv0.016. MA: mild asthma (untreated asthma); SA: severe asthma
(corticosteroid-dependent asthma); COPD: chronic obstructive pulmonary disease; MMP: metalloproteinase; TIMP: tissue-inhibitor metallopro-
teinase; NS: nonsignificant.
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plausible that elastase, through the damage of the elastic
fibres network both in central and peripheral airways, may be
responsible for the reduced airways patency and elastic recoil
during breathing [53]. This finding further suggests that
airflow limitation in these subjects could be attributed not
only to airway alterations, but also to parenchymal destruc-
tion, and provides a model that incorporates imaging and
functional abnormalities with biological markers.
It is worth noticing that three severe asthmatics showed
parenchymal alterations suggestive of emphysema. This might
have influenced the results of the study and needs to be taken
into account. The clinical characterisation of the patients was
critical in this study. Although it is difficult to clearly separate
some patients with COPD from asthmatics with permanent
airflow limitation [54, 55], the appropriateness of the
diagnosis is supported by the lack of response to inhaled b-
adrenergic agents, as well as by lower DL,CO and Pa,O2 values
measured in the COPD group.
The impact of age on elastase and a1-antitrypsin has not
been evaluated in the current study. However, the role of age
seems to be ruled out by the current authors9 recent obser-
vation that, in asthmatics, the alteration of the mechanisms
involved in the degradation of elastin is not enhanced by the
process of ageing [56]. An imbalance between proteinases and
their inhibitors has also been reported in individuals with
COPD, supporting the concept that this mechanism is a
feature of chronic bronchitis. Therefore, the current authors
feel confident that the disease status is the main determinant
of the imbalance in the enzymatic activity. The present
authors are also aware of the fact that structural alterations of
the lung could be associated with ageing processes. Indeed,
a re-arrangement of the elastic fibre network in the lungs
of elderly individuals has been demonstrated [47]. However,
the lung parenchyma of the elderly is characterised by a
homogeneous enlargement of airspaces without destruction
[57]. Therefore, the senile lung can be distinguished from the
emphysematous lung, where the airspace enlargement has an
irregular distribution with destruction. As a consequence, the
disease condition (either asthma or COPD) is responsible for
the radiological abnormalities, thus overcoming any possible
impact of the age-related structural alterations.
In conclusion, the present study demonstrates a close
relationship between high-resolution computed tomography
scan alterations and changes in the levels of markers of airway
remodelling, and suggests that biological markers might
reflect the structural changes occurring in the airways.
The use of high-resolution computed tomography to quantify
the extent of in vivo remodelling alterations is encouraged.
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Fig. 3. – Correlations between the levels of active elastase and high-
resolution computed tomography (HRCT) scan score in a) severe
asthmatic and b) chronic obstructive pulmonary disease subjects.
Statistical analysis was performed using the Spearman rank test.
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Fig. 4. – Correlations between the levels of metalloproteinase (MMP)-9/tissue-inhibitor metalloproteinase (TIMP)-1 ratio and high-resolution
computed tomography (HRCT) scan score in a) mild asthma (r=-0.8, pv0.003), b) severe asthma (r=-0.7, pv0.004), and c) chronic obstructive
pulmonary disease (r=-0.6, pv0.04). Statistical analysis was performed using the Spearman rank test.
915SPUTUM AND HRCT IN ASTHMA AND COPD
Acknowledgements. The work benefited from the
experience gained in the European Community
Programme GA2LEN, Global Allergy and Asthma
European Network.
References
1. Vignola AM, Kips J, Bousquet J. Tissue remodeling as a
feature of persistent asthma. J Allergy Clin Immunol 2000;
105: 1041–1053.
2. Vignola AM, Bonanno A, Mirabella A, et al. Increased levels
of elastase and a1-antitrypsin in sputum of asthmatic
patients. Am J Respir Crit Care Med 1998; 157: 505–511.
3. Fujita J, Nelson NL, Daughton DM, et al. Evaluation of
elastase and antielastase balance in patients with chronic
bronchitis and pulmonary emphysema. Am Rev Respir Dis
1990; 142: 57–62.
4. Murphy G, Docherty AJ. The matrix metalloproteinases and
their inhibitors. Am J Respir Cell Mol Biol 1992; 7: 120–125.
5. Vignola AM, Riccobono L, Mirabella A, et al. Sputum
metalloproteinase-9/tissue inhibitor of metalloproteinase-1
ratio correlates with airflow obstruction in asthma and
chronic bronchitis. Am J Respir Crit Care Med 1998; 158:
1945–1950.
6. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola
AM. Asthma. From bronchoconstriction to airways inflam-
mation and remodeling. J Allergy Clin Immunol 2000; 105:
1720–1745.
7. Cosio M, Ghezzo H, Hogg J, et al. The relations between
structural changes in small airways and pulmonary function
tests. N Engl J Med 1977; 298: 1277–1281.
8. Mautino G, Henriquet C, Jaffuel D, Bousquet J, Capony F.
Tissue inhibitor of metalloproteinase-1 levels in bronchoal-
veolar lavage fluid from asthmatic subjects. Am J Respir Crit
Care Med 1999; 160: 324–330.
9. Belvisi MG, Bottomley KM. The role of matrix metallopro-
teinases (MMPs) in the pathophysiology of chronic obstruc-
tive pulmonary disease (COPD): a therapeutic role for
inhibitors of MMPs? Inflamm Res 2003; 52: 95–100.
10. Cataldo D, Munaut C, Noel A, et al. Matrix metalloprotei-
nases and TIMP-1 production by peripheral blood granulo-
cytes from COPD patients and asthmatics. Allergy 2001; 56:
145–151.
11. Park JW, Hong YK, Kim CW, Kim DK, Choe KO, Hong
CS. High-resolution computed tomography in patients with
bronchial asthma: correlation with clinical features, pulmo-
nary functions and bronchial hyperresponsiveness. J Investig
Allergol Clin Immunol 1997; 7: 186–192.
12. Paganin F, Seneterre E, Chanez P, et al. Computed
tomography of the lungs in asthma: influence of disease
severity and etiology. Am J Respir Crit Care Med 1996; 153:
110–114.
13. Paganin F, Vignola AM, Seneterre E, Bruel JM, Chanez P,
Bousquet J. Heterogeneity of airways obstruction in asth-
matic patients using high-resolution computed tomography.
Chest 1995; 107: Suppl. 3, 145S–146S.
14. Bergin C, Muller N, Nichols D, et al. The diagnosis of
emphysema: a computed tomographic-pathologic corre-
lation. Am Rev Respir Dis 1986; 133: 541–546.
15. Baldi S, Miniati M, Bellina C, et al. Relationship between
extent of pulmonary emphysema by high-resolution com-
puted tomography and lung elastic recoil in patients with
chronic obstructive pulmonary disease. Am Rev Respir Dis
2001; 164: 585–589.
16. Niimi A, Matsumoto H, Amitani R, et al. Airway wall
thickness in asthma assessed by computed tomography.
Relation to clinical indices. Am J Respir Crit Care Med 2000;
162: 1518–1523.
17. Little S, Sproule M, Cowan M, et al. High resolution
computed tomographic assessment of airway wall thickness
in chronic asthma: reproducibility and relationship with lung
function and severity. Thorax 2002; 57: 247–253.
18. American Thoracic Society. Definitions and classifications of
chronic bronchitis, asthma and emphysema. Am Rev Respir
Dis 1962; 85: 762–768.
19. WHO/NHLBI workshop report. Global strategy for asthma
management and prevention. Bethesda, National Institutes
of Health, National Heart, Lung and Blood Institute
(publication no. 95-3659), 1995.
20. Gagliardo R, Chanez P, Vignola AM, et al. Glucocorticoid
receptor alpha and beta in glucocorticoid dependent asthma.
Am J Respir Crit Care Med 2000; 162: 7–13.
21. Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR.
Development and validation of the Mini Asthma Quality of
Life Questionnaire. Eur Respir J 1999; 14: 32–38.
22. Standards for the diagnosis and care of patients with chronic
obstructive pulmonary disease (COPD) and asthma. This
official statement of the American Thoracic Society was
adopted by the ATS Board of Directors, November 1986.
Am Rev Respir Dis 1987; 136: 225–244.
23. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic
inflammation in asthma. N Engl J Med 1990; 323: 1033–1039.
24. Knudson R, Slavin R, Lebowitz M, Burrows B. The
maximum expiratory flow volume curve: normal standards,
variability and effects of age. Am Rev Respir Dis 1976; 113:
587–600.
25. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC.
Standardization of the measurement of transfer factor
(diffusing capacity). Report Working Party Standardization
of Lung Function Tests, European Community for Steel and
Coal. Official Statement of the European Respiratory
Society. Eur Respir J 1993; 6: Suppl. 16, 41–52.
26. Quanjer PH, Tammeling GJ, Cotes JE, et al. Symbols,
abbreviations and units. Working Party Standardization of
Lung Function Tests, European Community for Steel and
Coal. Eur Respir J 1993; 6: Suppl. 16, 85–100.
27. Mayo JR, Webb WR, Gould R, et al. High-resolution CT of
the lungs: an optimal approach. Radiology 1987; 163: 507–
510.
28. Seneterre E, Paganin F, Bruel JM, Michel FB, Bousquet J.
Measurement of the internal size of bronchi using high
resolution computed tomography (HRCT). Eur Respir J
1994; 7: 596–600.
29. Webb WR, Gamsu G, Wall SD, Cann CE, Proctor E. CT of
a bronchial phantom. Factors affecting appearance and size
measurements. Invest Radiol 1984; 19: 394–398.
30. Lucidarme O, Grenier P, Coche E, Lenoir S, Aubert B,
Beigelman C. Bronchiectasis: comparative assessment with
thin-section CT and helical CT. Radiology 1996; 200: 673–
679.
31. Remy-Jardin M, Remy J. Comparison of vertical and
oblique CT in evaluation of bronchial tree. J Comput
Assist Tomogr 1988; 12: 956–962.
32. Kim JS, Muller NL, Park CS, Grenier P, Herold CJ.
Cylindrical bronchiectasis: diagnostic findings on thin-
section CT. AJR Am J Roentgenol 1997; 168: 751–754.
33. Stern EJ, Frank MS. CT of the lung in patients with
pulmonary emphysema: diagnosis, quantification, and cor-
relation with pathologic and physiologic findings. AJR Am
J Roentgenol 1994; 162: 791–798.
34. Austin JH, Muller NL, Friedman PJ, et al. Glossary of terms
for CT of the lungs: recommendations of the Nomenclature
Committee of the Fleischner Society. Radiology 1996; 200:
327–331.
35. Eda S, Kubo K, Fujimoto K, Matsuzawa Y, Sekiguchi M,
Sakai F. The relations between expiratory chest CT using
helical CT and pulmonary function tests in emphysema. Am
J Respir Crit Care Med 1997; 155: 1290–1294.
36. Reiff DB, Wells AU, Carr DH, Cole PJ, Hansell DM. CT
findings in bronchiectasis: limited value in distinguishing
between idiopathic and specific types. AJR Am J Roentgenol
1995; 165: 261–267.
916 A.M. VIGNOLA ET AL.
37. Paganin F, Trussard V, Seneterre E, et al. Chest radiography
and high resolution computed tomography of the lungs in
asthma. Am Rev Respir Dis 1992; 146: 1084–1087.
38. Pin I, Freitag AP, O9Byrne PM, et al. Changes in the cellular
profile of induced sputum after allergen-induced asthmatic
responses. Am Rev Respir Dis 1992; 145: 1265–1269.
39. Neumann S, Gunzer G, Hennrich N, Lang H. "PMN-
elastase assay": enzyme immunoassay for human polymor-
phonuclear elastase complexed with alpha 1-proteinase
inhibitor. J Clin Chem Clin Biochem 1984; 22: 693–697.
40. Okazawa M, Muller N, McNamara A, Child S, Verburgt L,
Pare P. Human airway narrowing measured using high
resolution computed tomography. Am J Respir Crit Care
Med 1996; 154: 1557–1562.
41. King G, Mu¨ller N, Pare´ P. Evaluation of airways in
obstructive pulmonary disease using high-resolution com-
puted tomography. Am J Respir Crit Care Med 1999; 159:
992–1004.
42. Nakano Y, Mu¨ller N, King G, et al. Quantitative assessment
of airway remodeling using high-resolution CT. Chest 2002;
122: Suppl. 6, 271S–275S.
43. Niimi A, Matsumoto H, Amitani R, et al. Airway wall
thickness in asthma assessed by computed tomography:
relation to clinical indices. Am J Respir Crit Care Med 2000;
162: 1518–1523.
44. Boulet L, Belanger M, Carrier G. Airway responsiveness and
bronchial-wall thickness in asthma with or without fixed
airflow obstruction. Am J Respir Crit Care Med 1995; 152:
865–871.
45. Nakano Y, Muro S, Sakai H, et al. Computed tomographic
measurements of airway dimensions and emphysema in
smokers: correlation with lung function. Am J Respir Crit
Care Med 2000; 162: 1102–1108.
46. Loubeyre P, Paret M, Revel D, Wiesendanger T, Brune J.
Thin-section CT detection of emphysema associated with
bronchiectasis and correlation with pulmonary function
tests. Chest 1996; 109: 360–365.
47. Janoff A. Elastases and emphysema. Current assessment of
the protease-antiprotease hypothesis. Am Rev Respir Dis
1985; 132: 417–433.
48. Stockley RA. The role of proteinases in the pathogenesis of
chronic bronchitis. Am J Respir Crit Care Med 1994; 150:
S109–S113.
49. Bousquet J, Lacoste J, Chanez P, Vic P, Godard P, Michel F.
Bronchial elastic fibers in normal subjects and asthmatic
patients. Am J Respir Crit Care Med 1996; 153: 1648–
1653.
50. Mauad T, Xavier AC, Saldiva PH, Dolhnikoff M. Elastosis
and fragmentation of fibers of the elastic system in
fatal asthma. Am J Respir Crit Care Med 1999; 160: 968–
975.
51. Gelb AF, Zamel N. Unsuspected pseudophysiologic emphy-
sema in chronic persistent asthma. Am J Respir Crit Care
Med 2000; 162: 1778–1782.
52. Matrisian LM. The matrix-degrading metalloproteinases.
Bioessays 1992; 14: 455–463.
53. Wright RR. Elastic tissue of normal and emphysematous
lungs. A tridimentional histologic study. Am J Pathol 1961;
34: 355–363.
54. O9Connor GT, Sparrow D, Weiss ST. The role of allergy and
nonspecific airway hyperresponsiveness in the pathogenesis
of chronic obstructive pulmonary disease. Am Rev Respir Dis
1989; 140: 225–252.
55. Snider GL. Chronic obstructive pulmonary disease: a
definition and implications of structural determinants of
airflow obstruction for epidemiology. Am Rev Respir Dis
1989; 140: S3–S8.
56. Vignola AM, Bonanno A, Profita M, et al. Effect of age and
asthma duration upon elastase and alpha1-antitrypsin levels
in adult asthmatics. Eur Respir J 2003; 22: 795–801.
57. Verbeken E, Cauberghs M, Mertens I, Clement J, Lauwryns
J, Van de Woestijne K. The senile lung: comparison with
normal and emphysematous lungs. 1. Structural aspects.
Chest 1992; 101: 793–799.
917SPUTUM AND HRCT IN ASTHMA AND COPD
